| Arman C. Moshyedi, Md, Pllc | |
|
8405 Greensboro Dr Ste 120 Mc Lean VA 22102-5106 | |
| (416) 915-9100 | |
| Not Available |
| Full Name | Arman C. Moshyedi, Md, Pllc |
|---|---|
| Speciality | Psychiatry & Neurology |
| Location | 8405 Greensboro Dr Ste 120, Mc Lean, Virginia |
| Authorized Official Name and Position | William Leonard (CEO) |
| Authorized Official Contact | 4169159100 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Arman C. Moshyedi, Md, Pllc 890 Yonge Street 7th Floor Toronto ON M4W3P-4 Ph: () - | Arman C. Moshyedi, Md, Pllc 8405 Greensboro Dr Ste 120 Mc Lean VA 22102-5106 Ph: (416) 915-9100 |
| NPI Number | 1366005183 |
|---|---|
| Provider Enumeration Date | 04/17/2019 |
| Last Update Date | 03/19/2024 |
| Certification Date | 03/19/2024 |
| Medicare PECOS PAC ID | 7911331665 |
|---|---|
| Medicare Enrollment ID | O20200106000809 |
News Archive
Novartis announced today that the US Food and Drug Administration has approved the dual combination bronchodilator Utibron Neohaler (indacaterol/glycopyrrolate) inhalation powder for the long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. It is not indicated to treat asthma or sudden symptoms of COPD.
University of Toronto researchers have shown that "designer molecules" can interact with the body's insulin receptor, a step toward the development of an oral medication for diabetes. U of T professors Lakshmi Kotra, Cecil Yip, Peter Ottensmeyer and Robert Batey have created the first small molecules using the three-dimensional structure of the insulin receptor. A receptor is the site on the surface of a cell to which molecules with specific tasks, such as hormones, attach themselves. Insulin's task is to initiate the utilization of sugar in the blood.
Women diagnosed with invasive breast cancer are 39% more likely to develop a second cancer in a different part of the body. Such is the conclusion of a recent study, pioneered by female Spanish researchers.
A clinical trial is being launched in three African countries of a drug that could eliminate onchocerciasis, or river blindness, one of the leading infectious causes of blindness across Africa. The drug, moxidectin, is being investigated for its potential to kill or sterilize the adult worms of Onchocerca volvulus, which cause onchocerciasis.
› Verified 3 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1366005183 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | (* (Not Available)) | Primary |
| 261Q00000X | Clinic/center | (* (Not Available)) | Secondary |
| Provider Name | Madan Uprety |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1528109758 PECOS PAC ID: 6406888163 Enrollment ID: I20090203000270 |
News Archive
Novartis announced today that the US Food and Drug Administration has approved the dual combination bronchodilator Utibron Neohaler (indacaterol/glycopyrrolate) inhalation powder for the long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. It is not indicated to treat asthma or sudden symptoms of COPD.
University of Toronto researchers have shown that "designer molecules" can interact with the body's insulin receptor, a step toward the development of an oral medication for diabetes. U of T professors Lakshmi Kotra, Cecil Yip, Peter Ottensmeyer and Robert Batey have created the first small molecules using the three-dimensional structure of the insulin receptor. A receptor is the site on the surface of a cell to which molecules with specific tasks, such as hormones, attach themselves. Insulin's task is to initiate the utilization of sugar in the blood.
Women diagnosed with invasive breast cancer are 39% more likely to develop a second cancer in a different part of the body. Such is the conclusion of a recent study, pioneered by female Spanish researchers.
A clinical trial is being launched in three African countries of a drug that could eliminate onchocerciasis, or river blindness, one of the leading infectious causes of blindness across Africa. The drug, moxidectin, is being investigated for its potential to kill or sterilize the adult worms of Onchocerca volvulus, which cause onchocerciasis.
› Verified 3 days ago
| Provider Name | Alok Kumar |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1639373202 PECOS PAC ID: 6406995588 Enrollment ID: I20100721000221 |
News Archive
Novartis announced today that the US Food and Drug Administration has approved the dual combination bronchodilator Utibron Neohaler (indacaterol/glycopyrrolate) inhalation powder for the long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. It is not indicated to treat asthma or sudden symptoms of COPD.
University of Toronto researchers have shown that "designer molecules" can interact with the body's insulin receptor, a step toward the development of an oral medication for diabetes. U of T professors Lakshmi Kotra, Cecil Yip, Peter Ottensmeyer and Robert Batey have created the first small molecules using the three-dimensional structure of the insulin receptor. A receptor is the site on the surface of a cell to which molecules with specific tasks, such as hormones, attach themselves. Insulin's task is to initiate the utilization of sugar in the blood.
Women diagnosed with invasive breast cancer are 39% more likely to develop a second cancer in a different part of the body. Such is the conclusion of a recent study, pioneered by female Spanish researchers.
A clinical trial is being launched in three African countries of a drug that could eliminate onchocerciasis, or river blindness, one of the leading infectious causes of blindness across Africa. The drug, moxidectin, is being investigated for its potential to kill or sterilize the adult worms of Onchocerca volvulus, which cause onchocerciasis.
› Verified 3 days ago
| Provider Name | William Michael Sauve |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1194847178 PECOS PAC ID: 0244385508 Enrollment ID: I20141217000230 |
News Archive
Novartis announced today that the US Food and Drug Administration has approved the dual combination bronchodilator Utibron Neohaler (indacaterol/glycopyrrolate) inhalation powder for the long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. It is not indicated to treat asthma or sudden symptoms of COPD.
University of Toronto researchers have shown that "designer molecules" can interact with the body's insulin receptor, a step toward the development of an oral medication for diabetes. U of T professors Lakshmi Kotra, Cecil Yip, Peter Ottensmeyer and Robert Batey have created the first small molecules using the three-dimensional structure of the insulin receptor. A receptor is the site on the surface of a cell to which molecules with specific tasks, such as hormones, attach themselves. Insulin's task is to initiate the utilization of sugar in the blood.
Women diagnosed with invasive breast cancer are 39% more likely to develop a second cancer in a different part of the body. Such is the conclusion of a recent study, pioneered by female Spanish researchers.
A clinical trial is being launched in three African countries of a drug that could eliminate onchocerciasis, or river blindness, one of the leading infectious causes of blindness across Africa. The drug, moxidectin, is being investigated for its potential to kill or sterilize the adult worms of Onchocerca volvulus, which cause onchocerciasis.
› Verified 3 days ago
| Provider Name | Geoffrey G Grammer |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1528141017 PECOS PAC ID: 8426375825 Enrollment ID: I20161202000253 |
News Archive
Novartis announced today that the US Food and Drug Administration has approved the dual combination bronchodilator Utibron Neohaler (indacaterol/glycopyrrolate) inhalation powder for the long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. It is not indicated to treat asthma or sudden symptoms of COPD.
University of Toronto researchers have shown that "designer molecules" can interact with the body's insulin receptor, a step toward the development of an oral medication for diabetes. U of T professors Lakshmi Kotra, Cecil Yip, Peter Ottensmeyer and Robert Batey have created the first small molecules using the three-dimensional structure of the insulin receptor. A receptor is the site on the surface of a cell to which molecules with specific tasks, such as hormones, attach themselves. Insulin's task is to initiate the utilization of sugar in the blood.
Women diagnosed with invasive breast cancer are 39% more likely to develop a second cancer in a different part of the body. Such is the conclusion of a recent study, pioneered by female Spanish researchers.
A clinical trial is being launched in three African countries of a drug that could eliminate onchocerciasis, or river blindness, one of the leading infectious causes of blindness across Africa. The drug, moxidectin, is being investigated for its potential to kill or sterilize the adult worms of Onchocerca volvulus, which cause onchocerciasis.
› Verified 3 days ago
| Provider Name | Seth Rosenblatt |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1770902355 PECOS PAC ID: 9739407594 Enrollment ID: I20170609001044 |
News Archive
Novartis announced today that the US Food and Drug Administration has approved the dual combination bronchodilator Utibron Neohaler (indacaterol/glycopyrrolate) inhalation powder for the long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. It is not indicated to treat asthma or sudden symptoms of COPD.
University of Toronto researchers have shown that "designer molecules" can interact with the body's insulin receptor, a step toward the development of an oral medication for diabetes. U of T professors Lakshmi Kotra, Cecil Yip, Peter Ottensmeyer and Robert Batey have created the first small molecules using the three-dimensional structure of the insulin receptor. A receptor is the site on the surface of a cell to which molecules with specific tasks, such as hormones, attach themselves. Insulin's task is to initiate the utilization of sugar in the blood.
Women diagnosed with invasive breast cancer are 39% more likely to develop a second cancer in a different part of the body. Such is the conclusion of a recent study, pioneered by female Spanish researchers.
A clinical trial is being launched in three African countries of a drug that could eliminate onchocerciasis, or river blindness, one of the leading infectious causes of blindness across Africa. The drug, moxidectin, is being investigated for its potential to kill or sterilize the adult worms of Onchocerca volvulus, which cause onchocerciasis.
› Verified 3 days ago
| Provider Name | Sanju Adhikari |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1225441066 PECOS PAC ID: 7810115615 Enrollment ID: I20180809000414 |
News Archive
Novartis announced today that the US Food and Drug Administration has approved the dual combination bronchodilator Utibron Neohaler (indacaterol/glycopyrrolate) inhalation powder for the long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. It is not indicated to treat asthma or sudden symptoms of COPD.
University of Toronto researchers have shown that "designer molecules" can interact with the body's insulin receptor, a step toward the development of an oral medication for diabetes. U of T professors Lakshmi Kotra, Cecil Yip, Peter Ottensmeyer and Robert Batey have created the first small molecules using the three-dimensional structure of the insulin receptor. A receptor is the site on the surface of a cell to which molecules with specific tasks, such as hormones, attach themselves. Insulin's task is to initiate the utilization of sugar in the blood.
Women diagnosed with invasive breast cancer are 39% more likely to develop a second cancer in a different part of the body. Such is the conclusion of a recent study, pioneered by female Spanish researchers.
A clinical trial is being launched in three African countries of a drug that could eliminate onchocerciasis, or river blindness, one of the leading infectious causes of blindness across Africa. The drug, moxidectin, is being investigated for its potential to kill or sterilize the adult worms of Onchocerca volvulus, which cause onchocerciasis.
› Verified 3 days ago
| Provider Name | Kevin Moore |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1023096054 PECOS PAC ID: 4688804289 Enrollment ID: I20181130000437 |
News Archive
Novartis announced today that the US Food and Drug Administration has approved the dual combination bronchodilator Utibron Neohaler (indacaterol/glycopyrrolate) inhalation powder for the long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. It is not indicated to treat asthma or sudden symptoms of COPD.
University of Toronto researchers have shown that "designer molecules" can interact with the body's insulin receptor, a step toward the development of an oral medication for diabetes. U of T professors Lakshmi Kotra, Cecil Yip, Peter Ottensmeyer and Robert Batey have created the first small molecules using the three-dimensional structure of the insulin receptor. A receptor is the site on the surface of a cell to which molecules with specific tasks, such as hormones, attach themselves. Insulin's task is to initiate the utilization of sugar in the blood.
Women diagnosed with invasive breast cancer are 39% more likely to develop a second cancer in a different part of the body. Such is the conclusion of a recent study, pioneered by female Spanish researchers.
A clinical trial is being launched in three African countries of a drug that could eliminate onchocerciasis, or river blindness, one of the leading infectious causes of blindness across Africa. The drug, moxidectin, is being investigated for its potential to kill or sterilize the adult worms of Onchocerca volvulus, which cause onchocerciasis.
› Verified 3 days ago
| Provider Name | Richard Rosse |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1316049570 PECOS PAC ID: 6800196965 Enrollment ID: I20200124000298 |
News Archive
Novartis announced today that the US Food and Drug Administration has approved the dual combination bronchodilator Utibron Neohaler (indacaterol/glycopyrrolate) inhalation powder for the long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. It is not indicated to treat asthma or sudden symptoms of COPD.
University of Toronto researchers have shown that "designer molecules" can interact with the body's insulin receptor, a step toward the development of an oral medication for diabetes. U of T professors Lakshmi Kotra, Cecil Yip, Peter Ottensmeyer and Robert Batey have created the first small molecules using the three-dimensional structure of the insulin receptor. A receptor is the site on the surface of a cell to which molecules with specific tasks, such as hormones, attach themselves. Insulin's task is to initiate the utilization of sugar in the blood.
Women diagnosed with invasive breast cancer are 39% more likely to develop a second cancer in a different part of the body. Such is the conclusion of a recent study, pioneered by female Spanish researchers.
A clinical trial is being launched in three African countries of a drug that could eliminate onchocerciasis, or river blindness, one of the leading infectious causes of blindness across Africa. The drug, moxidectin, is being investigated for its potential to kill or sterilize the adult worms of Onchocerca volvulus, which cause onchocerciasis.
› Verified 3 days ago
| Provider Name | Nishant Parikh |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1972860229 PECOS PAC ID: 0547499311 Enrollment ID: I20220310000755 |
News Archive
Novartis announced today that the US Food and Drug Administration has approved the dual combination bronchodilator Utibron Neohaler (indacaterol/glycopyrrolate) inhalation powder for the long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. It is not indicated to treat asthma or sudden symptoms of COPD.
University of Toronto researchers have shown that "designer molecules" can interact with the body's insulin receptor, a step toward the development of an oral medication for diabetes. U of T professors Lakshmi Kotra, Cecil Yip, Peter Ottensmeyer and Robert Batey have created the first small molecules using the three-dimensional structure of the insulin receptor. A receptor is the site on the surface of a cell to which molecules with specific tasks, such as hormones, attach themselves. Insulin's task is to initiate the utilization of sugar in the blood.
Women diagnosed with invasive breast cancer are 39% more likely to develop a second cancer in a different part of the body. Such is the conclusion of a recent study, pioneered by female Spanish researchers.
A clinical trial is being launched in three African countries of a drug that could eliminate onchocerciasis, or river blindness, one of the leading infectious causes of blindness across Africa. The drug, moxidectin, is being investigated for its potential to kill or sterilize the adult worms of Onchocerca volvulus, which cause onchocerciasis.
› Verified 3 days ago
| Provider Name | Scott Williams |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1285605840 PECOS PAC ID: 9436391547 Enrollment ID: I20221220001957 |
News Archive
Novartis announced today that the US Food and Drug Administration has approved the dual combination bronchodilator Utibron Neohaler (indacaterol/glycopyrrolate) inhalation powder for the long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. It is not indicated to treat asthma or sudden symptoms of COPD.
University of Toronto researchers have shown that "designer molecules" can interact with the body's insulin receptor, a step toward the development of an oral medication for diabetes. U of T professors Lakshmi Kotra, Cecil Yip, Peter Ottensmeyer and Robert Batey have created the first small molecules using the three-dimensional structure of the insulin receptor. A receptor is the site on the surface of a cell to which molecules with specific tasks, such as hormones, attach themselves. Insulin's task is to initiate the utilization of sugar in the blood.
Women diagnosed with invasive breast cancer are 39% more likely to develop a second cancer in a different part of the body. Such is the conclusion of a recent study, pioneered by female Spanish researchers.
A clinical trial is being launched in three African countries of a drug that could eliminate onchocerciasis, or river blindness, one of the leading infectious causes of blindness across Africa. The drug, moxidectin, is being investigated for its potential to kill or sterilize the adult worms of Onchocerca volvulus, which cause onchocerciasis.
› Verified 3 days ago
News Archive
Novartis announced today that the US Food and Drug Administration has approved the dual combination bronchodilator Utibron Neohaler (indacaterol/glycopyrrolate) inhalation powder for the long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. It is not indicated to treat asthma or sudden symptoms of COPD.
University of Toronto researchers have shown that "designer molecules" can interact with the body's insulin receptor, a step toward the development of an oral medication for diabetes. U of T professors Lakshmi Kotra, Cecil Yip, Peter Ottensmeyer and Robert Batey have created the first small molecules using the three-dimensional structure of the insulin receptor. A receptor is the site on the surface of a cell to which molecules with specific tasks, such as hormones, attach themselves. Insulin's task is to initiate the utilization of sugar in the blood.
Women diagnosed with invasive breast cancer are 39% more likely to develop a second cancer in a different part of the body. Such is the conclusion of a recent study, pioneered by female Spanish researchers.
A clinical trial is being launched in three African countries of a drug that could eliminate onchocerciasis, or river blindness, one of the leading infectious causes of blindness across Africa. The drug, moxidectin, is being investigated for its potential to kill or sterilize the adult worms of Onchocerca volvulus, which cause onchocerciasis.
› Verified 3 days ago
Risa E. Sanders, Ph.d., Pllc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 1313 Vincent Pl, Mc Lean, VA 22101 Phone: 703-919-1959 | |
Clementine Twin Lakes, Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 8180 Greensboro Dr Ste 375, Mc Lean, VA 22102 Phone: 571-569-4929 Fax: 571-762-0865 | |
Tysons Psychiatry Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 8200 Greensboro Dr, Suite 120, Mc Lean, VA 22102 Phone: 703-782-4588 Fax: 703-782-4591 | |
Supportive Care Aba Va Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 1765 Greensboro Station Pl, Mc Lean, VA 22102 Phone: 317-936-1240 Fax: 317-936-1241 | |
Mclean Psychiatric Services Llc Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 6832 Old Dominion Dr Ste 200, Mc Lean, VA 22101 Phone: 703-336-2406 | |
Kimberly M. Brooks Lpc Pllc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 6723 Whittier Ave Ste 206, Mc Lean, VA 22101 Phone: 571-481-1712 | |
Center For Pastoral Counseling Of Virginia Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 1716 Chain Bridge Rd, Mc Lean, VA 22101 Phone: 703-903-9696 |